Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
Top Cited Papers
- 1 December 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (12), 4055-4063
- https://doi.org/10.1182/blood-2007-07-102061
Abstract
The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second-generation drugs, nilotinib and dasatinib, displaying increased potency against BCR-ABL were developed. To predict potential side effects and novel medical uses, we generated comprehensive drug-protein interaction profiles by chemical proteomics for all 3 drugs. Our studies yielded 4 major findings: (1) The interaction profiles of the 3 drugs displayed strong differences and only a small overlap covering the ABL kinases. (2) Dasatinib bound in excess of 30 Tyr and Ser/Thr kinases, including major regulators of the immune system, suggesting that dasatinib might have a particular impact on immune function. (3) Despite the high specificity of nilotinib, the receptor tyrosine kinase DDR1 was identified and validated as an additional major target. (4) The oxidoreductase NQO2 was bound and inhibited by imatinib and nilotinib at physiologically relevant drug concentrations, representing the first nonkinase target of these drugs.This publication has 41 references indexed in Scilit:
- The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProceedings of the National Academy of Sciences of the United States of America, 2007
- Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factorBritish Journal of Cancer, 2006
- AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLBritish Journal of Cancer, 2006
- Regulating the regulator: negative regulation of Cbl ubiquitin ligasesTrends in Biochemical Sciences, 2006
- ILK, PINCH and parvin: the tIPP of integrin signallingNature Reviews Molecular Cell Biology, 2005
- Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profilingImmunological Reviews, 2005
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Identification and Characterization of a Novel MAP Kinase Kinase Kinase, MLTKOnline Journal of Public Health Informatics, 2001
- Chronic Myeloid LeukemiaThe New England Journal of Medicine, 1999